Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome
Pinto-Sanchez MI, Hall GB, Ghajar K, et al.
Published in Gastroenterology
Abstract
Randomised double-blind placebo-controlled pilot trial of B. longum NCC3001 with functional MRI in IBS patients with mild anxiety or depression.
Key Findings
B. longum NCC3001 reduced depression scores in IBS patients versus placebo at 6 weeks and altered limbic brain responses, but did not significantly reduce anxiety or core IBS symptoms.
Conclusions
Benefit appears specific to mood rather than bowel symptoms in this pilot.
Limitations
Pilot sample, single centre, primary IBS endpoints not met.
Supplements Studied
B. longum NCC3001 reduced depression scores in IBS patients versus placebo at 6 weeks and altered limbic brain responses, but did not significantly reduce anxiety or core IBS symptoms.
Outcomes Measured
B. longum NCC3001 reduced depression scores in IBS patients versus placebo at 6 weeks and altered limbic brain responses, but did not significantly reduce anxiety or core IBS symptoms.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.